Chemours (NYSE: CC) Investor Investigation

For Investors Who Bought Chemours Stock Between February 20, 2026 and August 4, 2026 | Serving PA, NJ, NY, MD & DC

Short answer. The Siddons Law Firm is investigating whether Chemours (NYSE: CC), the Wilmington, Delaware chemical company, gave investors accurate information about demand for its Opteon refrigerants and about its 2026 earnings guidance. On August 4, 2026 the company reported second-quarter results, said sales of Opteon refrigerant blends into the aftermarket had fallen, and cut its full-year adjusted EBITDA guidance to $775 million to $825 million from $800 million to $900 million. The stock fell 18.6 percent the next day. If you lost $100,000 or more in Chemours stock, or you are a current or former employee with firsthand knowledge, email msiddons@siddonslaw.com.

Last updated October 14, 2026.

Tell Us About Your Chemours Loss

Email msiddons@siddonslaw.com or use the form below. Give us the dates you bought and sold CC, the number of shares and the approximate amount you lost. Tell us if you work or have worked for Chemours. We will reply with the list of documents we need.

    Key Facts

    Company The Chemours Company (NYSE: CC), Wilmington, Delaware
    What happened Second-quarter 2026 results showed volume down about 4 percent, mainly from lower aftermarket sales of Opteon refrigerant blends, and the company cut its full-year adjusted EBITDA guidance to $775 million to $825 million from $800 million to $900 million (August 4, 2026, after the market closed)
    Date August 4, 2026
    Stock price Fell $3.34 per share, 18.6 percent, to close at $14.59 on August 5, 2026
    Period under review Purchases from February 20, 2026 through August 4, 2026
    Has a case been filed? Yes. A securities class action, Darcy v. The Chemours Company, No. 1:26-cv-01299, is pending in the United States District Court for the District of Delaware.
    Deadline to ask to lead the case December 7, 2026
    Source Chemours fourth-quarter 2025 results and 2026 outlook (February 2026) and second-quarter 2026 results (August 4, 2026)

    What Happened at Chemours?

    Chemours makes Opteon, a line of low-global-warming refrigerants, and sells it both to equipment makers and into the aftermarket for servicing existing systems. In February 2026 the company gave 2026 guidance that assumed continued aftermarket demand. On August 4, 2026, after the market closed, it reported second-quarter results showing volume down about 4 percent, attributed mainly to lower aftermarket sales of Opteon blends, and cut its full-year adjusted EBITDA guidance to $775 million to $825 million from $800 million to $900 million. The stock closed at $17.93 on August 4 and $14.59 on August 5, a fall of 18.6 percent.

    What Had Chemours Told Investors Before That?

    Between February and August 2026 Chemours told investors, among other things:

    • That aftermarket demand for its Opteon products was strong and supported its 2026 guidance.
    • That its 2026 financial guidance reflected its view of demand across its refrigerant business.

    The question under review is whether the company had sold more product into the channel in 2025 than end customers were using, so that aftermarket demand in 2026 was already falling when the guidance was given.

    What Is the Firm Investigating?

    We are investigating whether Chemours’s statements about demand for its Opteon refrigerant products and its 2026 guidance were accurate and complete when they were made, and whether investors who bought the stock between February 20, 2026 and August 4, 2026 paid more than it was worth as a result. Those questions arise under Section 10(b) of the Securities Exchange Act of 1934 and SEC Rule 10b-5.

    This is an investigation. No court has found that Chemours or its officers did anything wrong.

    Who Should Contact the Firm?

    • Investors who lost $100,000 or more in Chemours stock bought between February 20, 2026 and August 4, 2026. Shares held in an IRA or other retirement account count.
    • Trusts, estates, retirement plans, partnerships and businesses that held Chemours stock during that period.
    • Current and former Chemours employees who know firsthand what the company knew about Opteon demand, channel inventory and the 2026 guidance. Do not send company documents. Tell us in your own words what you saw. You may also qualify for a whistleblower award.

    If you lost less than $100,000, you generally do not need your own lawyer. Keep your trade confirmations and account statements. If a class action settles, you will need them to file a claim.

    What Should I Send?

    Send five facts to msiddons@siddonslaw.com:

    1. The dates you bought and sold CC.
    2. The number of shares.
    3. The prices you paid, if you have them.
    4. Your approximate loss.
    5. Whether you work or have worked for Chemours.

    Do not send documents through this website. We will reply with the list of documents we need.

    What Are the Deadlines?

    A class action is on file. Any investor who wants to ask the court to be appointed lead plaintiff must file that request by December 7, 2026. You do not have to be lead plaintiff to share in any recovery.

    A securities fraud claim generally must be filed within two years after the facts are discovered and no later than five years after the violation.

    Frequently Asked Questions

    Has a lawsuit been filed against Chemours?

    Yes. A securities class action was filed in the District of Delaware on behalf of investors who bought Chemours stock between February 20, 2026 and August 4, 2026. The deadline to ask the court to serve as lead plaintiff is December 7, 2026.

    I lost less than $100,000 in CC. What should I do?

    Keep your trade confirmations and account statements. If a class action is filed and you bought during the class period, you are generally a member of the class without doing anything. If the case settles, you will need your records to file a claim.

    I still own my CC shares. Does that matter?

    No. What matters is that you bought during the period under review and held shares when the news came out. Investors who sold after the price fell, and investors who still hold, can both have a claim.

    I work for Chemours. Can I contact the firm?

    Yes. What you tell us is confidential. Do not send company documents or anything the company’s lawyers told you. Federal law protects employees who report securities violations from retaliation, and the SEC whistleblower program pays an award of 10 to 30 percent of the money collected when a report leads to sanctions of more than $1 million.

    What does it cost to have my Chemours loss reviewed?

    The first conversation is free. If we take your matter, the fee terms are put in writing before any work begins.

    Email Us About Chemours

    Email msiddons@siddonslaw.com with the dates you bought and sold CC, the number of shares and your approximate loss. Attorney Michael A. Siddons represents investors in Pennsylvania, New Jersey, New York, Maryland and Washington, D.C.